GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CinCor Pharma Inc (NAS:CINC) » Definitions » 14-Day RSI

CinCor Pharma (CinCor Pharma) 14-Day RSI : N/A (As of Jun. 09, 2024)


View and export this data going back to 2022. Start your Free Trial

What is CinCor Pharma 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-06-09), CinCor Pharma's 14-Day RSI is N/A.

The industry rank for CinCor Pharma's 14-Day RSI or its related term are showing as below:

CINC's 14-Day RSI is not ranked *
in the Biotechnology industry.
Industry Median: 45.11
* Ranked among companies with meaningful 14-Day RSI only.

Competitive Comparison of CinCor Pharma's 14-Day RSI

For the Biotechnology subindustry, CinCor Pharma's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CinCor Pharma's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CinCor Pharma's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where CinCor Pharma's 14-Day RSI falls into.



CinCor Pharma  (NAS:CINC) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CinCor Pharma  (NAS:CINC) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


CinCor Pharma 14-Day RSI Related Terms

Thank you for viewing the detailed overview of CinCor Pharma's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


CinCor Pharma (CinCor Pharma) Business Description

Traded in Other Exchanges
N/A
Address
200 Clarendon Street, 6th Floor, Boston, MA, USA, 02116
CinCor Pharma Inc is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases.
Executives
Sofinnova Management X-a, L.l.c. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
James Healy director, 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Michael Wayne Kalb officer: EVP & Chief Financial Officer 24 LUCILLE LANE, DIX HILLS NY 11746
5am Opportunities Ii (gp), Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISO CA 94107
5am Opportunities Ii, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Vi, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Partners Sas Sofinnova 10 percent owner 17 RUE DE SERENE, PARIS I0 75008
Maha Katabi 10 percent owner SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Venture Partners X, L.p. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Management X, L.l.c. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
General Atlantic Genpar (bermuda), L.p. 10 percent owner C/O GENERAL ATLANTIC SERVICE COMPANY,LLC, 55 EAST 52ND ST. 32ND FLOOR, NEW YORK NY 10055
General Atlantic, L.p. 10 percent owner 55 EAST 52ND STREET, 33RD FLOOR, NEW YORK NY 10055
Mason Freeman officer: EVP Clinical Development C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Mary Theresa Coelho officer: EVP CFO & Chief BD Officer 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Garidel Marc De director, officer: Chief Executive Officer C/O CINCOR PHARMA, INC., 200 CLARENDON STREET, 6TH FLOOR, BOSTON MA 02116

CinCor Pharma (CinCor Pharma) Headlines

From GuruFocus